PMID- 6164480
OWN - NLM
STAT- MEDLINE
DCOM- 19810720
LR  - 20220331
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 47
IP  - 9
DP  - 1981 May 1
TI  - The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study.
PG  - 2302-11
AB  - One-hundred-eighty-eight children up to 16 years of age were randomized in the 
      second National Wilms' Tumor Study (NWTS) with tumors that were confined to the 
      kidney and that had been totally excised (Group I). Most fared well whether 
      treated for six or for 15 months with both actinomycin D (AMD) and vincristine 
      (VCR). No postoperative radiation therapy (RT) was given. The two-year 
      relapse-free survival (RFS) and two-year survival rates were 88 and 95%, 
      respectively. Two-hundred-sixty-eight randomized patients with more advanced 
      local lesions (Groups II and III) and 57 with distant metastases (Group IV) had 
      postoperative RT and were scheduled for 15 months treatment with either AMD and 
      VCR (Reg. C) or AMD plus VCR plus Adriamycin (Reg. D). The 77% two-year RFS rate 
      for Reg. D was significantly different from the 63% with Reg. C. As in the first 
      NWTS, patients with tumors of unfavorable histology (UH) had a significantly 
      worse prognosis than those with favorable histology (FH), as did those with 
      positive nodes. Survival rates at two years were 54% for UH vs. 90% for FH, and 
      54% vs. 82% for those with and without lymph node involvement.
FAU - D'Angio, G J
AU  - D'Angio GJ
FAU - Evans, A
AU  - Evans A
FAU - Breslow, N
AU  - Breslow N
FAU - Beckwith, B
AU  - Beckwith B
FAU - Bishop, H
AU  - Bishop H
FAU - Farewell, V
AU  - Farewell V
FAU - Goodwin, W
AU  - Goodwin W
FAU - Leape, L
AU  - Leape L
FAU - Palmer, N
AU  - Palmer N
FAU - Sinks, L
AU  - Sinks L
FAU - Sutow, W
AU  - Sutow W
FAU - Tefft, M
AU  - Tefft M
FAU - Wolff, J
AU  - Wolff J
LA  - eng
GR  - CA 11722/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Clinical Trials as Topic
MH  - Dactinomycin/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - Humans
MH  - Infant
MH  - Kidney Neoplasms/*drug therapy/radiotherapy/surgery
MH  - Male
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Nephrectomy
MH  - Probability
MH  - Prognosis
MH  - Vincristine/therapeutic use
MH  - Wilms Tumor/*drug therapy/radiotherapy/surgery
EDAT- 1981/05/01 00:00
MHDA- 1981/05/01 00:01
CRDT- 1981/05/01 00:00
PHST- 1981/05/01 00:00 [pubmed]
PHST- 1981/05/01 00:01 [medline]
PHST- 1981/05/01 00:00 [entrez]
AID - 10.1002/1097-0142(19810501)47:9<2302::aid-cncr2820470933>3.0.co;2-k [doi]
PST - ppublish
SO  - Cancer. 1981 May 1;47(9):2302-11. doi: 
      10.1002/1097-0142(19810501)47:9<2302::aid-cncr2820470933>3.0.co;2-k.